Methods and compositions for targeting gc1qr/p32

Abstract

Disclosed are compositions and methods useful for targeting gC1q/p32 receptors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells, and to areas of inflammation.

1 - 6 . (canceled) 
     
     
         7 . A method of detecting the presence of gC1q/p32 receptor, the method comprising
 a. bringing into contact a cell and a Lyp-1 composition, wherein the Lyp-1 composition comprises a moiety linked to a composition comprising SEQ ID NO:1; and   b. detecting interaction between gC1q/p32 receptor and the Lyp-1 composition, thereby detecting the presence of gC1q/p32 receptor.   
     
     
         8 . The method of  claim 7 , wherein the moiety is a detectable agent, a polypeptide, a nucleic acid molecule, or a small molecule. 
     
     
         9 . The method of  claim 7 , wherein the Lyp-1 composition comprises a virus. 
     
     
         10 . The method of  claim 7 , wherein the Lyp-1 composition comprises a phage. 
     
     
         11 . The method of  claim 8 , wherein the detectable agent is a small molecule, a fluorophore, fluorescein, rhodamine, a radionuclide, indium-111, technetium-99, carbon-11, carbon-13, or a combination thereof. 
     
     
         12 . A method of detecting interaction between a gC1q/p32 receptor and a Lyp-1 composition, wherein the Lyp-1 composition comprises a moiety linked to a composition comprising SEQ ID NO:1, the method comprising:
 a. selecting a cell for its potential to comprise a gC1q/p32 receptor;   b. bringing into contact the Lyp-1 composition and the cell; and   c. detecting interaction between the gC1q/p32 receptor and the Lyp-1 composition.   
     
     
         13 . The method of  claim 12 , wherein the moiety is a detectable agent. 
     
     
         14 . The method of  claim 12 , wherein the moiety is a polypeptide, a nucleic acid molecule, a small molecule, a fluorophore, fluorescein, rhodamine, a radionuclide, indium-111, technetium-99, carbon-11, carbon-13, or a combination thereof. 
     
     
         15 - 17 . (canceled) 
     
     
         18 . A method of assessing gC1q/p32 receptor level in a cell of a subject, comprising:
 a. bringing into contact a cell of the subject and a Lyp-1 composition comprising a detectable agent linked to a composition comprising SEQ ID NO:1; and   b. detecting the level of Lyp-1 composition interacting with gC1q/p32 receptor, thereby assessing gC1q/p32 receptor level in the cell.   
     
     
         19 . The method of  claim 18 , wherein the level of gC1q/p32 receptor in the subject is compared to a previous measurement in the same subject. 
     
     
         20 . The method of  claim 18 , wherein the level of gC1q/p32 receptor in the subject is compared to a control level or standard level. 
     
     
         21 . A method of identifying a subject having a disease associated with gC1q/p32 receptor, the method comprising
 a. bringing into contact a cell of the subject and a Lyp-1 composition, wherein the Lyp-1 composition comprises a moiety linked to a composition comprising SEQ ID NO:1; and   b. detecting interaction between gC1q/p32 receptor and the Lyp-1 composition, thereby detecting the presence or level of gC1q/p32, wherein the presence or level of gC1q/p32 receptor identifies the subject as having a disease associated with a gC1q/p32 receptor.   
     
     
         22 . The method of  claim 21 , wherein the disease is cancer. 
     
     
         23 . The method of  claim 21 , wherein the cell is a cancerous cell. 
     
     
         24 . A method of screening for a compound that interacts with a gC1q/p32 receptor, comprising:
 a. bringing into contact a test compound, a Lyp-1 composition, and a gC1q/p32 receptor, wherein the Lyp-1 composition comprises SEQ ID NO:1; and   b. detecting unbound Lyp-1 composition, wherein a given amount of unbound Lyp-1 composition indicates a compound that interacts with gC1q/p32 receptor.   
     
     
         25 . The method of  claim 24 , wherein the Lyp-1 composition further comprises a moiety linked to a composition comprising SEQ ID NO:1. 
     
     
         26 . The method of  claim 25 , wherein the moiety further comprises a detectable agent. 
     
     
         27 - 28 . (canceled) 
     
     
         29 . The method of  claim 12 , wherein the cell is in an organism, in a subject, in situ, ex vivo, in culture, or in vitro. 
     
     
         30 . (canceled) 
     
     
         31 . A method, the method comprising administering to the subject a composition that modulates gC1q/p32 receptor expression or activity, wherein the subject has cancer cells having an elevated level of gC1q/p32 receptor compared with non-cancerous cells in the subject. {*page 20, lines 22-29, page 67, lines 28-30, and page 68, lines 4-10*} 
     
     
         32 . The method of  claim 31 , wherein the disease is cancer. 
     
     
         33 . The method of  claim 31 , wherein expression or activity of the gC1q/p32 receptor is inhibited. 
     
     
         34 . The method of  claim 33 , wherein expression of the gC1q/p32 receptor is inhibited using an interfering nucleic acid. 
     
     
         35 . The method of  claim 34 , wherein the interfering nucleic acid is siRNA. 
     
     
         36 . The method of  claim 33 , wherein the activity of the gC1q/p32 receptor is inhibited by a LyP-1 peptide, an antibody, or a small molecule mimic of Lyp-1. 
     
     
         37 . The method of  claim 18 , wherein the cell is in an organism, in a subject, in situ, ex vivo, in culture, or in vitro. 
     
     
         38 . The method of  claim 21 , wherein the cell is in an organism, in a subject, in situ, ex vivo, in culture, or in vitro. 
     
     
         39 . The method of  claim 24 , wherein the cell is in an organism, in a subject, in situ, ex vivo, in culture, or in vitro.